ALFA Filings
Every announcement, straight from the exchange
Every Jagsonpal Pharmaceuticals merger & restructuring announcement on NSE and BSE, newest first, each with its own page.
Time
11 announcements
Jagsonpal Pharmaceuticals has completed the acquisition of an 85% equity stake in Aequitas Healthcare. This follows initial acquisition intimations made in June 2026.
Jagsonpal Pharmaceuticals completed the acquisition of a 69.77% stake in Aequitas Healthcare, turning it into a subsidiary. No monetary value was disclosed.
Jagsonpal Pharmaceuticals is acquiring an 85% stake in Aequitas Healthcare for ₹20.78 Crore. This strategic move provides access to hospital channels and institutional doctor networks.
Jagsonpal Pharmaceuticals will acquire an 85% stake in Aequitas Healthcare for ₹20.8 Crore. The transaction marks its strategic entry into the hospital segment.
Jagsonpal Pharmaceuticals extinguished 16,00,000 equity shares following a successful buyback via tender offer. The post-buyback paid-up capital now stands at Rs. 13.11 Crore.
Jagsonpal Pharmaceuticals completed a ₹40 Crore equity share buyback via the tender offer route. The company repurchased 1,600,000 shares, increasing promoter holding to 69.36%.
Jagsonpal Pharmaceuticals Ltd announced a share buyback of 16,00,000 equity shares via a tender offer at ₹250 per share. The total buyback size is capped at ₹40 Crore. The offer opens on May 8, 2026, and closes on May 14, 2026, aimed at returning capital to shareholders.
Jagsonpal Pharmaceuticals Limited announced a buyback of up to 16,00,000 equity shares at ₹250 per share, totalling ₹40 Crore. The buyback, representing 2.38% of paid-up capital, opens on May 08, 2026, and closes on May 14, 2026.
Jagsonpal Pharmaceuticals Limited announced a buyback of up to 16,00,000 equity shares at ₹250 per share, totaling ₹40 Crore. The buyback will be conducted via a tender offer on a proportionate basis. The company has fixed May 4, 2026, as the record date to determine eligible shareholders for the offer.
Jagsonpal Pharmaceuticals Limited has fixed May 04, 2026, as the record date for its buy-back of up to 16,00,000 equity shares. The buy-back is priced at ₹250 per share for a total aggregate amount of ₹40 Crore. This event determines shareholder eligibility for participation in the buy-back program.
Jagsonpal Pharmaceuticals Ltd secured shareholder approval for a buyback of up to 16 lakh equity shares at ₹250 each. The transaction, totaling ₹40 Crore, aims to optimize capital allocation and improve earnings per share.